Celgene's (NASDAQ:CELG) new psoriatic arthritis drug Otezla isn't going to beat the current offerings from AbbVie (NYSE:ABBV), Johnson & Johnson (NYSE:JNJ), and Amgen (NASDAQ:AMGN) on an efficacy basis.

But it doesn't have too. Unlike Humira, Remicade, Enbrel, and the rest of the injected or infused biologics, Otezla is taken orally, giving Celgene a distinct advantage over AbbVie, Johnson & Johnson, and Amgen.

That doesn't mean Otezla will be an instant blockbuster though. As Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss in the video below, Celgene needs to find a sweat spot, positioning Otezla between oral generics and the biologics doctors are comfortable prescribing.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.